Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Biotechnology

Healthcare
$149.40 -2.22%

-$6.27 today

Market cap
$20.01B
Beta
0.27
P/E (TTM)
63.6
EPS (TTM)
$4.34
52W Low $273.11High $495.55

Volume 2.52M

Average 1.11M

ALNY Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Alnylam Pharmaceuticals, Inc.NASDAQ: ALNY

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 138.25M shares rose 6.6% year over year, in line with the +6.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +6.6% holds above the trailing-twelve-month pace of +6.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
138.25M+0.0% QoQ
Last fiscal yearDec 2025
134.68M+5.5% YoY
LTMJun 2026
137.53M+6.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.6%——
1 year+5.5%——
3-year CAGR+3.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
134.68M USD
Year-over-year change
+5.5%
4-year CAGR
+3.3%

Weighted Avg Shares (Diluted) vs competitors

How ALNY compares with its peers on the latest reported figures

  • ALNY's LTM Jun 2026 weighted avg shares (diluted) of 137.53M shares is the 4th highest of the 6 companies compared; the peer median is 142.03M shares.
  • Its year-over-year change of +6.5% is the 3rd highest of 5, against a peer median of +7.8%.
  • Over three fiscal years its annual growth of +3.4% compares with a peer median of +12.1%.
ALNY Competitors Peer median
Weighted Avg Shares (Diluted) for ALNY and competitors
Company Period LTM YoY 3-year CAGR
WVEWave Life Sciences Ltd.LTM Mar 2026178.01M +19.3%+28.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M -0.2%+4.1%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026142.03M +6.4%+9.9%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026137.53M +6.5%+3.4%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
Peer median (excluding ALNY) 142.03M+7.8%+12.1%

Competitors are the stored peer set for ALNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue844.29M1.04B1.83B2.25B3.71B
Cost of Revenue140.14M168.82M310.41M323.37M677.17M
Gross Profit704.14M868.6M1.52B1.92B3.04B
Gross Margin83.4%83.7%83.0%85.6%81.8%
Research & Development792.16M883.02M1B1.13B1.32B
Selling, General & Admin620.64M770.66M795.65M975.53M1.21B
Operating Expenses1.41B1.65B1.8B2.1B2.54B
Depreciation & Amortization47.57M44.47M54.05M56.67M55.66M
EBITDA(661.56M)(926.56M)(258.24M)(178.85M)631.44M
EBITDA Margin-78.4%-89.3%-14.1%-8.0%17.0%
Operating Income(708.65M)(785.07M)(282.18M)(176.89M)501.58M
Operating Margin-83.9%-75.7%-15.4%-7.9%13.5%
Interest Income1.58M24.81M95.56M121.99M111.47M
Interest Expense143.02M155.97M121.22M141.86M252.63M
Other Income / Expenses(143.49M)(341.92M)(151.34M)(200.49M)(178.43M)
Income Before Tax(852.14M)(1.13B)(433.52M)(377.38M)323.15M
Pre-Tax Margin-100.9%-108.6%-23.7%-16.8%8.7%
Income Tax Expense680K4.16M6.73M(99.22M)9.41M
Net Income(852.82M)(1.13B)(440.24M)(278.16M)313.75M
Net Margin-101.0%-109.0%-24.1%-12.4%8.4%
EPS (Basic)(7.20)(9.30)(3.52)(2.18)2.39
EPS (Diluted)(7.20)(9.30)(3.52)(2.18)2.33
Weighted Avg Shares118.45M121.69M124.91M127.65M131M
Weighted Avg Shares (Diluted)118.45M121.69M124.91M127.65M134.68M

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Intrinsic Alpha fair value

Locked

Current Price

$149.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.